Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atossa Therapeutics ( (ATOS) ) has shared an update.
On February 11, 2026, Atossa Therapeutics issued a shareholder letter reviewing 2025 progress and outlining its 2026 outlook, highlighting advances in its (Z)-endoxifen programs across breast cancer and rare diseases. The company detailed positive preliminary data from I-SPY 2 neoadjuvant monotherapy studies in ER+/HER2- breast cancer, progress in combination arms with partners Eli Lilly and AbbVie, and a strategic decision to pause investment in metastatic breast cancer trials after an IND clearance to concentrate resources on higher-return indications.
Atossa emphasized expanding (Z)-endoxifen into non-oncology indications, including Duchenne muscular dystrophy, where it secured Rare Pediatric Disease and Orphan Drug designations from the FDA in late 2025 and early 2026, as well as work in female DMD carriers and McCune-Albright Syndrome. The company also strengthened its foundation through new patents on enteric oral formulations, ongoing USPTO proceedings to defend manufacturing IP, key leadership hires in R&D and finance, a 2025 industry R&D award, maintenance of more than $40 million in cash entering 2026, and a reverse stock split effective February 2, 2026 to support continued Nasdaq listing compliance.
The most recent analyst rating on (ATOS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.
Spark’s Take on ATOS Stock
According to Spark, TipRanks’ AI Analyst, ATOS is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and rising TTM cash burn) and a strongly bearish technical setup (price far below key moving averages with negative MACD). Positive FDA-related corporate milestones provide some support, but valuation is difficult to justify with negative earnings and no dividend.
To see Spark’s full report on ATOS stock, click here.
More about Atossa Therapeutics
Atossa Therapeutics, Inc. is a Seattle-based clinical-stage biopharmaceutical company focused on developing novel therapies in oncology and other areas of high unmet medical need, centered on its proprietary oral (Z)-endoxifen. The company targets breast cancer and select rare diseases driven by estrogen signaling, while building a differentiated intellectual property portfolio and preparing for future commercialization.
Average Trading Volume: 123,635
Technical Sentiment Signal: Sell
Current Market Cap: $45.99M
For an in-depth examination of ATOS stock, go to TipRanks’ Overview page.